ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026
Impact of pulmonary hypertension on mortality in progressive massive fibrosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe aim of this study was to investigate the factors affecting the development of pulmonary hypertension (PH) in patients with progressive massive fibrosis (PMF) and to determine the relationship between PH development and life expectancy.
methodsIn this retrospective study, 181 patients with PMF were recruited over a 9-year period and 96 were eligible for analysis. We used echocardiography (ECHO) findings to estimate the likelihood of developing PH. We used Bernoulli's equation with tricuspid regurgitation velocity measurement and calculated systolic pulmonary artery pressure (sPAP) by adding the estimated right atrial pressure. We accepted sPAP values of 37 and 50 mm Hg as criteria for moderate and high probability PH.
resultsThe prevalence of moderate or high probability PH (PH group) was 29.1% in patients with PMF. Older age (OR:1.059, p=0.036) and presence of C opacity (OR:4.607, p=0.024) were found to be risk factors for PH in patients with PMF. The survival rate (39.2%) and mean survival time (65.20±9.94 months) were significantly lower in the PH group compared to the non-PH group (p=0.002). PH development was primarily associated with fibrotic disease burden rather than coexisting airflow obstruction.
conclusionsThe development of PH and the increase in the degree of PH have a negative effect on the mean survival time. Preventing the development of PMF, which has a poor prognosis, by taking necessary precautions is the most effective option in treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.